You can learn more from our asked questions
Find clear answers to the most common questions about Semaglutide, Tirzepatide, and Retatrutide, all based on the latest clinical research and scientific data.
Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone in your body to regulate appetite and blood sugar. When prescribed for weight management, it helps you feel full sooner, reduce calorie intake, and achieve clinically proven weight loss【1】.
Tirzepatide is a dual-action treatment that activates both GLP-1 and GIP receptors. This makes it even more effective than Semaglutide for some patients, with trials showing average weight loss of over 20% of body weight【2】.
Retatrutide is a triple-action therapy (GLP-1, GIP, and glucagon). Early studies show it may deliver the greatest weight loss results yet over 24% of body weight in under a year 【3】. Availability is still expanding, and it may not yet be suitable for all patients.
- Ozempic® is a brand name for Semaglutide, originally developed for type 2 diabetes.
- Wegovy® is Semaglutide specifically licensed for weight loss.
- Mounjaro® is the brand name for Tirzepatide.
At Nuvio Labs, we provide access to the active medications (Semaglutide, Tirzepatide, Retatrutide), prescribed by UK doctors through licensed clinics.
These treatments work best when combined with a healthy diet and regular physical activity. Nuvio Labs provides support and resources to help you make sustainable lifestyle changes alongside your treatment.
All medicines can have side effects, but these treatments have undergone rigorous clinical trials with thousands of patients. Common side effects include nausea, bloating, or mild digestive issues, which usually improve with time.
Your Nuvio Labs doctor will carefully review your health before prescribing to ensure safety.
All three treatments are once-weekly injections, typically self-administered using a pre-filled pen or vial. Your doctor and instructions will guide you step by step.
They are generally prescribed for:
- Adults with a BMI over 30, OR
- Adults with a BMI over 27 with weight-related conditions (e.g., type 2 diabetes, high blood pressure).
⚠️ They are not suitable for everyone (e.g., pregnant women, those with certain health conditions). A Nuvio Labs doctor will confirm suitability after your consultation.
Results vary, but many patients notice reduced appetite within weeks and steady weight loss over months. Clinical trials show significant results over 6–12 months with consistent use and lifestyle support.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM, 2022.
- Jastreboff AM, et al. Triple-Hormone Receptor Agonist Retatrutide in Adults with Obesity. NEJM, 2023.
Still have you any problem for solutions?
For any inquiries related to our research peptides, fat-loss studies, or scientific information about Semaglutide, Tirzepatide, or Retatrutide, feel free to contact us directly during business hours.
Call for help:
(843) 971-1906
Mail for information:
support@nuviolabs.uk
Head office address:
United Kingdom.
